Who are Interferon-Alfa 9MU's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gm-Csf, IL-2 (interleukin 2), PUVA (8MOP + UVA) + IFN, Late receiving G-CSF group, Interferon beta 1a, oral doxycycline, Early receiving G-CSF group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/interferon-alfa-9mu.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Interferon-Alfa 9MU — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interferon-Alfa 9MU (Interferon-Alfa 9MU) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine; Interferon. Area: Oncology; Immunology.

phase 3 Cytokine; Interferon Interferon-alpha receptor (IFNAR) Oncology; Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Interferon-Alfa 9MU (Interferon-Alfa 9MU) — Pfizer. Interferon-alfa activates the innate immune system by binding to interferon-alpha receptors on immune cells and tumor cells, enhancing antiviral and anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Interferon-Alfa 9MU TARGET	Interferon-Alfa 9MU	Pfizer	phase 3	Cytokine; Interferon	Interferon-alpha receptor (IFNAR)
Gm-Csf	gm-csf	Pfizer	marketed	cytokine	GM-CSF receptor	1991-01-01
IL-2 (interleukin 2)	IL-2 (interleukin 2)	King's College London	marketed	Cytokine	IL-2 receptor (IL-2R)
PUVA (8MOP + UVA) + IFN	PUVA (8MOP + UVA) + IFN	Madrilenian Group of Cutaneous Lymphomas	marketed	Photochemotherapy + cytokine combination
Late receiving G-CSF group	Late receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)
Interferon beta 1a, oral doxycycline	Interferon beta 1a, oral doxycycline	Louisiana State University Health Sciences Center Shreveport	marketed	Cytokine + tetracycline antibiotic combination	Interferon-beta receptor (IFNBR); doxycycline targets bacterial ribosomes and matrix metalloproteinases
Early receiving G-CSF group	Early receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine; Interferon class)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Pfizer · 1 drug in this class
Royal Marsden NHS Foundation Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Interferon-Alfa 9MU — Competitive Intelligence Brief. https://druglandscape.com/ci/interferon-alfa-9mu. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing